Avalon GloboCare Partners with Pounds Transformation Clinics to Unveil the KetoAir BrAce 4 Impact Challenge Series
Avalon GloboCare (NASDAQ: ALBT) has partnered with Pounds Transformation Clinics to launch the 'BrAce 4 Impact Challenge Series,' featuring their KetoAir™ breathalyzer devices. The partnership includes placing KetoAir devices on consignment at three Connecticut locations.
Following a successful pilot program ending March 18, 2025, the first official challenge begins April 1, 2025. The KetoAir device, FDA-registered (No. 3026284320), measures breath acetone concentration to track ketosis status through nano-sensor technology, accessible via Apple App Store and Google Play Store.
Early results show promising outcomes, with pilot participants reporting significant weight loss success while maintaining BrAce readings around 12ppm. Pounds Transformation plans to initiate new challenges every six weeks, supported by dedicated coaches for daily participant guidance.
Avalon GloboCare (NASDAQ: ALBT) ha stretto una partnership con Pounds Transformation Clinics per lanciare la serie di sfide 'BrAce 4 Impact Challenge Series', che presenta i loro dispositivi di alcol test KetoAir™. La partnership prevede il collocamento dei dispositivi KetoAir in consignment in tre sedi nel Connecticut.
Dopo un programma pilota di successo che si concluderà il 18 marzo 2025, la prima sfida ufficiale inizierà il 1 aprile 2025. Il dispositivo KetoAir, registrato dalla FDA (No. 3026284320), misura la concentrazione di acetone nel respiro per monitorare lo stato di chetosi attraverso la tecnologia dei nano-sensori, accessibile tramite Apple App Store e Google Play Store.
I primi risultati mostrano esiti promettenti, con i partecipanti al programma pilota che segnalano un significativo successo nella perdita di peso mantenendo letture BrAce intorno a 12ppm. Pounds Transformation prevede di avviare nuove sfide ogni sei settimane, supportate da allenatori dedicati per la guida quotidiana dei partecipanti.
Avalon GloboCare (NASDAQ: ALBT) se ha asociado con Pounds Transformation Clinics para lanzar la serie de desafíos 'BrAce 4 Impact Challenge Series', que presenta sus dispositivos de alcoholímetro KetoAir™. La asociación incluye la colocación de dispositivos KetoAir en consignación en tres ubicaciones en Connecticut.
Después de un exitoso programa piloto que finalizará el 18 de marzo de 2025, el primer desafío oficial comenzará el 1 de abril de 2025. El dispositivo KetoAir, registrado por la FDA (No. 3026284320), mide la concentración de acetona en el aliento para rastrear el estado de cetosis a través de tecnología de nano-sensores, accesible a través de Apple App Store y Google Play Store.
Los primeros resultados muestran resultados prometedores, con participantes del piloto que informan un éxito significativo en la pérdida de peso mientras mantienen lecturas de BrAce alrededor de 12ppm. Pounds Transformation planea iniciar nuevos desafíos cada seis semanas, apoyados por entrenadores dedicados para la guía diaria de los participantes.
아발론 글로보케어 (NASDAQ: ALBT)는 파운드 트랜스포메이션 클리닉과 협력하여 '브레이스 4 임팩트 챌린지 시리즈'를 출시하며, 이 시리즈에는 그들의 케토에어™ 호흡 측정 장치가 포함됩니다. 이 파트너십은 코네티컷의 세 곳에 케토에어 장치를 위탁 배치하는 내용을 포함합니다.
2025년 3월 18일 종료되는 성공적인 파일럿 프로그램에 이어, 첫 공식 챌린지는 2025년 4월 1일 시작됩니다. 케토에어 장치(FDA 등록번호: 3026284320)는 호흡 중 아세톤 농도를 측정하여 나노 센서 기술을 통해 케토시스 상태를 추적하며, Apple App Store와 Google Play Store를 통해 접근할 수 있습니다.
초기 결과는 유망한 성과를 보여주며, 파일럿 참가자들은 브레이스 수치가 12ppm 정도 유지되는 동안 상당한 체중 감소 성공을 보고했습니다. 파운드 트랜스포메이션은 매 6주마다 새로운 챌린지를 시작할 계획이며, 매일 참가자에게 안내를 제공하는 전담 코치가 지원할 것입니다.
Avalon GloboCare (NASDAQ: ALBT) a établi un partenariat avec Pounds Transformation Clinics pour lancer la série de défis 'BrAce 4 Impact Challenge Series', mettant en avant leurs dispositifs de breathalyzer KetoAir™. Ce partenariat comprend la mise en consignation des dispositifs KetoAir dans trois emplacements du Connecticut.
À la suite d'un programme pilote réussi qui se termine le 18 mars 2025, le premier défi officiel commencera le 1er avril 2025. Le dispositif KetoAir, enregistré auprès de la FDA (No. 3026284320), mesure la concentration d'acétone dans l'haleine pour suivre l'état de cétose grâce à une technologie de nano-capteurs, accessible via l'Apple App Store et le Google Play Store.
Les premiers résultats montrent des résultats prometteurs, avec des participants au programme pilote signalant un succès significatif dans la perte de poids tout en maintenant des lectures BrAce autour de 12ppm. Pounds Transformation prévoit de lancer de nouveaux défis tous les six semaines, soutenus par des coachs dédiés pour guider les participants au quotidien.
Avalon GloboCare (NASDAQ: ALBT) hat sich mit Pounds Transformation Clinics zusammengeschlossen, um die 'BrAce 4 Impact Challenge Series' zu starten, die ihre KetoAir™ Atemmessgeräte präsentiert. Die Partnerschaft umfasst die Platzierung von KetoAir-Geräten auf Kommission in drei Standorten in Connecticut.
Nach einem erfolgreichen Pilotprogramm, das am 18. März 2025 endet, beginnt die erste offizielle Herausforderung am 1. April 2025. Das KetoAir-Gerät, das von der FDA registriert ist (Nr. 3026284320), misst die Acetonkonzentration im Atem, um den Ketose-Status mithilfe von Nano-Sensortechnologie zu verfolgen, die über den Apple App Store und den Google Play Store zugänglich ist.
Frühe Ergebnisse zeigen vielversprechende Ergebnisse, wobei die Teilnehmer des Pilotprogramms von signifikanten Gewichtsverlusten berichten, während sie BrAce-Werte von etwa 12ppm aufrechterhalten. Pounds Transformation plant, alle sechs Wochen neue Herausforderungen zu starten, unterstützt von engagierten Coaches, die tägliche Anleitung für die Teilnehmer bieten.
- Expansion into three new retail locations in Connecticut
- Successful pilot program leading to regular challenge series implementation
- Strong customer testimonials showing product effectiveness
- to consignment-based sales model
- Geographic expansion restricted to single state currently
KetoAir Now In Stock at All Three Pounds Transformation Clinics in Connecticut
FREEHOLD, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced that it has partnered with Pounds Transformation Clinics, led by Dr. Charles Cavo, a member of the Zero to Keto Affiliate Marketing Program, to launch the “BrAce 4 Impact Challenge Series.” This new collaboration has already debuted its inaugural challenge in conjunction with Pounds Transformation’s 4-week Diet Challenge, incorporating KetoAir™ breathalyzer devices as a motivational tool. KetoAir™ devices are now available on consignment at all three Pounds Transformation locations in West Hartford Center, Southington, and Glastonbury, Connecticut.
Following the successful conclusion of the 4-week BrAce 4 Impact Challenge Pilot on March 18, 2025, Pounds Transformation is kicking off the first official BrAce 4 Impact Challenge starting April 1, 2025. “I saw a patient today from the BrAce 4 Impact Challenge pilot who is doing extremely well,” said Dr. Charles Cavo. “She uses the KetoAir™ three times a day and has never experienced this level of weight loss before. Her BrAce readings remain around 12ppm, and she’s never felt better. The KetoAir™ keeps her ‘honest’ and on track. With the level of results our patients are achieving with the help of the KetoAir™, it is our intent to begin new BrAce 4 Impact Challenges every six weeks,” added Dr. Cavo. To further support participants, Pounds Transformation has assigned a dedicated coach as the daily point of contact throughout the Challenge Series.
Pounds Transformation is a Connecticut-based health and wellness clinic focused on long-term weight management. Their programs address the root causes of weight gain through evidence-based interventions, ongoing support, and regular monitoring of key health markers.
KetoAir™ is a handheld breathalyzer, specifically engineered for ketogenic health management (United States FDA registration number: 3026284320). KetoAir™ measures an individual's breath acetone concentration (BrAce), a ketone body that rises as fat oxidation increases. By leveraging the nano-sensor-based technology, the KetoAir™ breathalyzer is designed to assess the ketosis status of its individual user and is accessible on both the Apple App Store and Google Play Store.
“We are very pleased with the expansion of our partnership with Pounds Transformation clinics,” said David Jin, M.D., Ph.D., CEO of Avalon GloboCare. “It’s rewarding to see the KetoAir™ device have such a positive impact on their patient programs, supporting real-time, personalized insights that empower individuals on their wellness journey. This partnership highlights our shared commitment to delivering innovative, accessible tools that improve health outcomes and encourage long-term lifestyle changes.”
“Integrating the KetoAir™ Breathalyzer into our programs allows our patients to track their ketone levels in real time, helping them stay motivated and engaged in their daily routines,” said Dr. Charles Cavo, Co-founder of Pounds Transformation. “Many of our patients have struggled with weight loss for years. KetoAir™ provides immediate feedback that helps validate their progress, reinforce positive behavior, and improve accountability. It’s become a valuable tool in helping our patients understand their bodies and take control of their health in a sustainable way.”
To learn more or purchase your own KetoAir™ device, visit www.ketoair.us.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products. Avalon is currently marketing the KetoAir™ breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. In addition, the company owns and operates commercial real estate. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates, however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of KetoAir™ and the product’s ability to compete with other testing methods for determining ketosis. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Form 8-Ks filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What are the key features of Avalon's KetoAir device (ALBT) for ketosis tracking?
Where can customers purchase KetoAir devices from Avalon (ALBT) in Connecticut?
What results are participants seeing in Avalon's (ALBT) BrAce 4 Impact Challenge?
How often will Avalon (ALBT) and Pounds Transformation launch new BrAce 4 Impact Challenges?
